Isis Secures Another Big Pharma Collaborator with Janssen Antisense Drug Discovery Deal
By Heather Cartwright
Pharma Deals Review: Vol 2015 Issue 1 (Table of Contents)
Published: 19 Jan-2015
DOI: 10.3833/pdr.v2015.i1.2088 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
In a deal worth up to US$835 M, Isis Pharmaceuticals has partnered with Janssen Biotech to discover and develop antisense drugs that can be locally targeted to treat autoimmune disorders of gastrointestinal tract, a therapeutic area of expertise for Janssen...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS